Social network
Media - Staying connected to our latest news and events
Media - Staying connected to our latest news and events


Staying connected to our latest news and events

Tools content (print, share, increase/decrease text size):


Middle area:

Press releases 2012

Press releases are intended to journalists, analysts and investors.

Merial to Acquire Animal Health Division of Dosch Pharmaceuticals in India

December 20, 2012

Sanofi President, Global Operations, to retire

December 18, 2012

Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1, 2013

December 18, 2012

Genzyme and Isis Provide Update on CHMP Opinion on KYNAMRO™ (mipomersen)

December 14, 2012

Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint

December 09, 2012

Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting

December 03, 2012

Sanofi launches Awareness Campaign for Air France passengers on the Risks of Counterfeit Medicines

November 30, 2012

Sanofi Ranks Third on the Access to Medicine Foundation’s 2012 ATM Index

November 28, 2012

Sanofi Donates $500,000 to Hurricane Sandy Immediate and Long-Term Relief Efforts

November 19, 2012

Sanofi Receives Positive CHMP Opinion in the European Union for Once-Daily Lyxumia® (lixisenatide)

November 16, 2012

ZALTRAP® (aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer

November 16, 2012

Sanofi Appoints Dr. Gary J. Nabel as Chief Scientific Officer

November 14, 2012

Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes

November 14, 2012

Sanofi and Institut Pasteur Honor Innovation in Biomedical Research with the Sanofi-Institut Pasteur 2012 Awards

November 13, 2012

Sanofi successfully prices EUR 750 million bond issue

November 07, 2012

Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia

November 05, 2012

Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The Lancet

October 31, 2012

Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine

October 31, 2012

Q3 2012 Business EPS reflects patent expirations. Growth Platforms reached over 70% of sales

October 25, 2012

FDA Advisory Committee Recommends KYNAMRO™ for Homozygous Familial Hypercholesterolemia

October 18, 2012

Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability

October 12, 2012

Sanofi to Launch State-of-the Art, Reusable Insulin Pen AllStar™ in India

October 09, 2012

Genzyme to Present New Data from AUBAGIO and LEMTRADA Clinical Development Programs at ECTRIMS

October 09, 2012

Sanofi Announces Final Results of its Modified Dutch Auction Tender Offer for its Outstanding Contingent Value Rights

October 08, 2012

Journal of Clinical Oncology Publishes Phase III Results of ZALTRAP® (aflibercept) VELOUR Study in Previously Treated Metastatic Colorectal Cancer

October 08, 2012

New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population

October 05, 2012

Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement

October 03, 2012

Sanofi to Acquire Genfar S.A., a Leader in Pharmaceutical Medicines in Colombia

October 02, 2012

Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Improved Glycemic Control

October 02, 2012

Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint

October 02, 2012

Sanofi appoints Dr. Paul Chew, Chief Medical Officer and Head of Global Medical Affairs

October 01, 2012

EASD Abstracts Highlight Sanofi Commitment to Advancing Therapeutic Solutions in Diabetes Care

September 26, 2012

Sanofi provides information on the adaptation of its activities in France through 2015

September 25, 2012

Sanofi and TB Alliance Announce Collaboration to Accelerate New Treatments Against Tuberculosis

September 20, 2012

FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis

September 12, 2012

Sanofi Pasteur Announces Publication in The Lancet of World's First Efficacy Results for its Dengue Vaccine Candidate

September 11, 2012

Sanofi Launches Modified Dutch Auction Tender Offer to Purchase up to 86,766,040 of its Outstanding Contingent Value Rights

September 04, 2012

Genzyme Provides Update on U.S. LEMTRADA™ Filing

August 27, 2012

Sanofi Announces FDA Approval for Auvi-Q™, First Voice-guided Epinephrine Auto-injector for Patients with Life-threatening Allergies

August 13, 2012

U.S. FDA Approves ZALTRAP® (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal Cancer

August 03, 2012

Availability Online of the Group’s Half-Year Financial Report for 2012

July 27, 2012

As expected, Q2 2012 Business EPS impacted by the loss of exclusivity of Plavix® and Avapro® in the U.S.

July 26, 2012

Sanofi Pasteur’s Dengue Vaccine Demonstrates Proof of Efficacy

July 25, 2012

Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program with LDL Cholesterol-Lowering PCSK9 Antibody

July 20, 2012

Sanofi to divest its stake in the Yves Rocher Group

July 04, 2012

Sanofi Pasteur’s 6-in-1 Pediatric Vaccine Hexaxim™ Receives Positive Opinion from European Medicines Agency

June 22, 2012

Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes

June 19, 2012

Sanofi Voted Leading Pan-European Quoted Company for Investor Relations in the 2012 Thomson Reuters Extel Survey

June 13, 2012

Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA™ (alemtuzumab) for Multiple Sclerosis

June 12, 2012

New Epidemiological Data Provide Additional Safety Evidence for Lantus®

June 11, 2012

Sanofi Announces Results of ORIGIN, the World’s Longest and Largest Randomized Clinical Trial in Pre- and Early Diabetes

June 11, 2012

Sanofi Submits Application for Regulatory Approval for Lyxumia® (lixisenatide) for the Treatment of Type 2 Diabetes in Japan

June 11, 2012

Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose

June 09, 2012

Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes

June 09, 2012

Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIO™ (teriflunomide) in Relapsing Multiple Sclerosis

June 01, 2012

Sanofi Inaugurates Lantus® SoloSTAR® Pen Assembly Plant in its Beijing Facility

May 28, 2012

Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet

May 26, 2012

ASCO Abstracts Highlight Late-stage Sanofi Oncology Pipeline

May 17, 2012

Combined General Shareholder Meeting of May 4, 2012

May 04, 2012

Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing Plant

May 03, 2012

Japan Chooses Sanofi Pasteur for First Enhanced Inactivated Polio Vaccine

April 27, 2012

Strong performance in Q1 2012 including Genzyme contribution

April 27, 2012

Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada™ (Alemtuzumab) Compared With Rebif® in Phase lll Trial

April 24, 2012

Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll Trials

April 20, 2012

Sanofi and Michael J. Fox Foundation Collaborate on Potential New Treatment for Parkinson’s Disease

April 19, 2012

Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap® (aflibercept

April 05, 2012

Merial Acquires Newport Laboratories

April 02, 2012

Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody

March 26, 2012

Sanofi to Acquire Pluromed, Inc., Expanding its Presence in Biosurgery

March 16, 2012

Filing of the 2011 U.S. Form 20-F and French “Document de Référence” Containing the Annual Financial Report

March 07, 2012

Composition of Sanofi’s Board of Directors

March 05, 2012

Sanofi appoints Jean-Luc Lowinski, Senior Vice President, Asia Region

March 02, 2012

Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant

March 01, 2012

Sanofi and the Institut Pasteur Create Four Prestigious Awards to Support Innovative Biomedical Research

February 27, 2012

2011 Results Benefit from Genzyme Acquisition. Net Sales and Business EPS up 9.2% in Q4

February 08, 2012

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

February 08, 2012

Sanofi Commits to Eliminate or Control Five Neglected Tropical Diseases

January 30, 2012

Genzyme Announces FDA Approval of Framingham Manufacturing Plant

January 24, 2012

Brazil Introduces Inactivated Polio Vaccine in National Immunization Program with Sanofi Pasteur Vaccine

January 18, 2012

Genzyme Announces European Approval of Framingham Manufacturing Plant

January 18, 2012

Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners, Jointly Launch Warp Drive Bio, a Biotechnology Company Combining Innovative Genomics Technologies for Natural Products Drug Discovery

January 10, 2012

Right area:




Filter by date


© Sanofi 2004-2016 - All rights reserved - Update: March 12, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)